Status:
COMPLETED
Prospective Primary Human Lungcancer Organoids to Predict Treatment Response
Lead Sponsor:
Maastricht Radiation Oncology
Conditions:
Lung Cancer
Eligibility:
All Genders
Brief Summary
Organoids are generated from tumor biopsies, taken during a standard procedure. and are a collection of organ-specific cell types that are able to self-organize in-vitro in a manner similar to the in-...
Detailed Description
One of the most important barriers to achieve durable responses in advanced lung cancer is intra- and inter-tumor heterogeneity, a common feature of human solid cancers. Tumor heterogeneity is thought...
Eligibility Criteria
Inclusion
- \- Undergo primary surgical resection of a primary lung cancer (e.g. wedge resection, segmental resection, lobectomy, pneumonectomy)
Exclusion
- \- Preceding induction treatment (e.g. induction chemotherapy or chemo-radiotherapy)
Key Trial Info
Start Date :
November 15 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2022
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT04859166
Start Date
November 15 2017
End Date
October 1 2022
Last Update
March 15 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Zuyderland Medical Center
Heerlen, Netherlands, 6419 PC
2
Maastro
Maastricht, Netherlands, 6229 ET